JAGX · Jaguar Health, Inc.
AI read · Neutral
The AI's read
The sales decline came as Jaguar shifted U.S. marketing of Mytesi and Canalevia-CA1 to Future Pak. Jaguar still makes those products, but U.S. sales go to Future Pak. Losses narrowed, and Jaguar also reduced its debt. It plans to seek approval for its rare-disease treatment in mid-2027, but that step has not happened yet. These facts point in different directions, so the report does not show a clear change in the company's outlook.